Effectiveness of Ketorolac Tromethamine 0.5% Ophthalmic Solution for Chronic Aphakic and Pseudophakic Cystoid Macular Edema

Ketorolac therapy for the prevention of acute pseudophakic cystoid macular edema: a systematic review

“…[9][10][11][12] The purpose of this systematic review is to assess the effectiveness of ketorolac vs control in the treatment of acute pseudophakic CME (necessitating therapeutic intervention within 4 months of CME onset). [13][14][15] …”

In vivo ocular availability of ketorolac following ocular instillations of aqueous, oil, and ointment formulations to normal corneas of rabbits: A technical note

“…9,10 Ophthalmic solution of KT (0.5%) has been shown to be effective in treatment of chronic aphakic and pseudoaphakic macular edema. 11 Beneficial effect of KT (0.5%) topical solution in reducing postoperative pain after laser in situ keratomileusis has been reported. 12 Previously this laboratory has reported in vitro transcorneal permeation of KT from 0.5% (wt/vol) aqueous drops, where formulation containing benzalkonium chloride (0.01% wt/vol) and disodium edetate (0.01% wt/vol) provided maximum corneal permeation.…”

Safety, tolerability, and bioavailability of topical SAR 1118, a novel antagonist of lymphocyte function-associated antigen-1: a phase 1b study

“…The treatment of pseudophakic cystoid macular oedema with topical non-steroidal anti-inflammatory medications offers an example of successful topical treatment of a macular disorder in the presence of an intact hyaloid. 18,19 It may be possible to chemically modify SAR 1118 to improve its posterior segment penetration when delivered topically. A recent report of successful reduction of uveitic macular oedema using subcutaneous injection of efalizumab, a humanized antibody directed against a subunit of LFA-1, 20 highlights the therapeutic potential of therapies designed to inhibit LFA-1/ICAM-1.…”